NASA Astrophysics Advisory Committee; Meeting, 10358-10359 [2021-03372]
Download as PDF
10358
Federal Register / Vol. 86, No. 32 / Friday, February 19, 2021 / Notices
Controlled substance
Drug code
tkelley on DSKBCP9HB2PROD with NOTICES
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ......................................................................................................
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ..................................................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ......................................................................................................
Ibogaine ...........................................................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
Marihuana Extract ...........................................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Mescaline .........................................................................................................................................................................
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ......................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
5-Methoxy-N–N-dimethyltryptamine ................................................................................................................................
Psilocyn ...........................................................................................................................................................................
4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) .....................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .......................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ......................................................................................................
Butylone ...........................................................................................................................................................................
Pentylone .........................................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................
Desomorphine .................................................................................................................................................................
Dihydromorphine .............................................................................................................................................................
Heroin ..............................................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................
Normorphine ....................................................................................................................................................................
Tilidine .............................................................................................................................................................................
Alpha-methylfentanyl .......................................................................................................................................................
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ...............................................................................
Methamphetamine ...........................................................................................................................................................
Phenmetrazine .................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Norfentanyl ......................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Meperidine intermediate-B ..............................................................................................................................................
Meperidine intermediate-C ..............................................................................................................................................
Methadone intermediate ..................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Morphine ..........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
14-Hydroxmorphone ........................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
The company plans to import the
listed controlled substances for sale to
research facilities for drug testing and
analysis. In reference to drug codes 7360
(Marihuana) and 7370
(Tetrahydrocannabinols) the company
plans to import a synthetic cannabidiol
and a synthetic tetrahydrocannabinol.
No other activities for these drug codes
are authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
VerDate Sep<11>2014
21:07 Feb 18, 2021
Jkt 253001
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–03381 Filed 2–18–21; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00126
Fmt 4703
Sfmt 4703
7118
7122
7144
7203
7260
7315
7350
7360
7370
7381
7398
7405
7431
7438
7498
7535
7540
7541
7542
9053
9055
9145
9200
9307
9313
9750
9814
9821
1105
1631
1724
2125
2270
2315
2550
7471
8333
8366
8501
9050
9120
9170
9180
9190
9193
9220
9230
9233
9234
9254
9273
9300
9333
9665
9668
9740
9801
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Notice: (21–009)]
NASA Astrophysics Advisory
Committee; Meeting
National Aeronautics and
Space Administration.
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, Public
SUMMARY:
E:\FR\FM\19FEN1.SGM
19FEN1
tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 86, No. 32 / Friday, February 19, 2021 / Notices
Law 92–463, as amended, the National
Aeronautics and Space Administration
(NASA) announces a meeting of the
Astrophysics Advisory Committee. This
Committee reports to the Director,
Astrophysics Division, Science Mission
Directorate, NASA Headquarters. The
meeting will be held for the purpose of
soliciting, from the scientific
community and other persons, scientific
and technical information relevant to
program planning.
DATES: Monday, March 15, 2021, 11:00
a.m.–5:00 p.m.; Tuesday, March 16,
2021, 11:00 a.m.–5:00 p.m.; and
Wednesday, March 17, 2021, 11:00
a.m.–5:00 p.m.; Eastern Time.
FOR FURTHER INFORMATION CONTACT: Ms.
KarShelia Henderson, Science Mission
Directorate, NASA Headquarters,
Washington, DC 20546, (202) 358–2355,
or khenderson@nasa.gov.
SUPPLEMENTARY INFORMATION: The
meeting will be available to the public
by WebEx.
On Monday, March 15, the event
address for attendees is: https://
nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=md56c2364
ad7f625bf9121430ef9d85f9, the meeting
number is 199 340 9228, and meeting
password is MJh8JVDV89@.
On Tuesday, March 16, the event
address for attendees is: https://
nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=
m1ce0a71960e457179b7e
85dcc41de62b, the meeting number is
199 888 1998, and meeting password is
csAvpYM2@78.
On Wednesday, March 17, the event
address for attendees is: https://
nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=
m26744d6e150f086b3cf3ed99bd6649fa,
the meeting number is 199 029 2743,
and meeting password is 9skWYje8P@3.
To join by telephone, the numbers
are: 1–929–251–9612 or 1–415–527–
5035, for each day.
The agenda for the meeting includes
the following topics:
—Astrophysics Division Update
—Updates on Specific Astrophysics
Missions
—Reports from the Program Analysis
Groups
—Reports from Specific Research and
Analysis Programs
The agenda will be posted on the
Astrophysics Advisory Committee web
page: https://science.nasa.gov/
researchers/nac/science-advisorycommittees/apac.
The public may submit and upvote
comments/questions ahead of the
meeting through the website https://
arc.cnf.io/sessions/mkky/#!/dashboard
VerDate Sep<11>2014
21:07 Feb 18, 2021
Jkt 253001
10359
that will be opened for input on March
1, 2021.
It is imperative that the meeting be
held on this date to accommodate the
scheduling priorities of the key
participants.
Dated: February 16, 2021.
Crystal Robinson,
Committee Management Officer.
Patricia Rausch,
Advisory Committee Management Officer,
National Aeronautics and Space
Administration.
NATIONAL SCIENCE FOUNDATION
[FR Doc. 2021–03372 Filed 2–18–21; 8:45 am]
BILLING CODE 7510–13–P
[FR Doc. 2021–03389 Filed 2–18–21; 8:45 am]
BILLING CODE 7555–01–P
Sunshine Act Meetings
The National Science Board (NSB) hereby
gives notice of the scheduling of meetings for
the transaction of NSB business as follows:
Tuesday, February 23,
2021, from 11:00 a.m. to 6:45 p.m., and
Wednesday, February 24, 2021, from
11:00 a.m. to 6:40 p.m. EST.
PLACE: These meetings will be held by
videoconference. There will be no inperson meetings. The public may
observe the public meetings, which will
be streamed to the NSF You Tube
channel. For meetings on Tuesday,
February 23, go to: https://youtu.be/
6JjWhwMhIKM. For meetings on
Wednesday, February 24, go to: https://
youtu.be/tmiQwe7o_Y0.
STATUS: Parts of these meetings will be
open to the public. The rest of the
meetings will be closed to the public.
See full description below.
MATTERS TO BE CONSIDERED:
TIME AND DATE:
NATIONAL SCIENCE FOUNDATION
Advisory Committee for International
Science and Engineering; Notice of
Meeting
In accordance with the Federal Advisory
Committee Act (Pub. L. 92–463, as amended),
the National Science Foundation (NSF)
announces the following meeting:
Name and Committee Code: Advisory
Committee for International Science and
Engineering Meeting (AC–ISE) (#25104).
Date and Time: Friday, March 19,
2021, 10:00 a.m. to 5:00 p.m. (Eastern
Time).
Place: NSF, 2415 Eisenhower Avenue,
Alexandria, VA 22314 | Virtual Zoom.
This AC–ISE meeting is fully virtual.
All public participants are required to
process the meeting registration via
Zoom.
Connect to The Virtual Meeting:
Register in advance for the meeting at
the Zoom attendee registration link:
https://nsf.zoomgov.com/webinar/
register/WN_
IRrGAhXcRO2DvpdH7jAVjA. After
registering, you will receive a
confirmation email with a unique link
to join the meeting.
If you have any login questions,
please contact Kirk Grabowski, OISE IT
Specialist: kgrabows@associates.nsf.gov.
Type of Meeting: Open.
Contact Person: Christopher Street,
National Science Foundation, 2415
Eisenhower Avenue, Room W–17220,
Alexandria, Virginia 22314; Telephone:
(703) 292–8568/Email: cstreet@nsf.gov.
Purpose of Meeting: To provide
advice, recommendations and counsel
on major goals and policies pertaining
to international programs and activities.
Agenda
• Updates on OISE activities
• Discussion on Global Leadership in
Science, Engineering, and Education
• Innovative Partnerships
• Meet with NSF leadership
PO 00000
Frm 00127
Fmt 4703
Sfmt 4703
Tuesday, February 23, 2021
Plenary Board Meeting
Open Session: 11:00 a.m.–1:05 p.m.
• NSB Chair’s Remarks
• New Member Swearing-in
Matthew Malkan
Scott Stanley
• NSF Director’s Remarks
• NSB Chair Activity Summary
• Racial Equity Task Force and NSF
Harassment Policy Update
• Vision 2030 Implementation Working
Group Update
Committee on Oversight (CO)
Open Session: 1:15 p.m.–2:25 p.m.
• Committee Chair’s Opening Remarks
• Approval of Committee Meeting
Minutes
• Broader Impacts—Update on
Activities
Discussion and action on statement
and resolution re: Reviewer
Training
Discussion and action on statement
and resolution re: Broader Impacts
Expert on Committees of Visitors
• Inspector General’s Update
• Chief Financial Officer’s Update
Committee on National Science and
Engineering Policy (SEP)
Open Session: 2:35 p.m.–3:25 p.m.
• Committee Chair’s Opening Remarks
E:\FR\FM\19FEN1.SGM
19FEN1
Agencies
[Federal Register Volume 86, Number 32 (Friday, February 19, 2021)]
[Notices]
[Pages 10358-10359]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03372]
=======================================================================
-----------------------------------------------------------------------
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
[Notice: (21-009)]
NASA Astrophysics Advisory Committee; Meeting
AGENCY: National Aeronautics and Space Administration.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, Public
[[Page 10359]]
Law 92-463, as amended, the National Aeronautics and Space
Administration (NASA) announces a meeting of the Astrophysics Advisory
Committee. This Committee reports to the Director, Astrophysics
Division, Science Mission Directorate, NASA Headquarters. The meeting
will be held for the purpose of soliciting, from the scientific
community and other persons, scientific and technical information
relevant to program planning.
DATES: Monday, March 15, 2021, 11:00 a.m.-5:00 p.m.; Tuesday, March 16,
2021, 11:00 a.m.-5:00 p.m.; and Wednesday, March 17, 2021, 11:00 a.m.-
5:00 p.m.; Eastern Time.
FOR FURTHER INFORMATION CONTACT: Ms. KarShelia Henderson, Science
Mission Directorate, NASA Headquarters, Washington, DC 20546, (202)
358-2355, or [email protected].
SUPPLEMENTARY INFORMATION: The meeting will be available to the public
by WebEx.
On Monday, March 15, the event address for attendees is: https://nasaenterprise.webex.com/nasaenterprise/j.php?MTID=md56c2364ad7f625bf9121430ef9d85f9, the meeting number is 199
340 9228, and meeting password is [email protected]
On Tuesday, March 16, the event address for attendees is: https://nasaenterprise.webex.com/nasaenterprise/j.php?MTID=m1ce0a71960e457179b7e85dcc41de62b, the meeting number is 199
888 1998, and meeting password is [email protected]
On Wednesday, March 17, the event address for attendees is: https://nasaenterprise.webex.com/nasaenterprise/j.php?MTID=m26744d6e150f086b3cf3ed99bd6649fa, the meeting number is 199
029 2743, and meeting password is [email protected]
To join by telephone, the numbers are: 1-929-251-9612 or 1-415-527-
5035, for each day.
The agenda for the meeting includes the following topics:
--Astrophysics Division Update
--Updates on Specific Astrophysics Missions
--Reports from the Program Analysis Groups
--Reports from Specific Research and Analysis Programs
The agenda will be posted on the Astrophysics Advisory Committee
web page: https://science.nasa.gov/researchers/nac/science-advisory-committees/apac.
The public may submit and upvote comments/questions ahead of the
meeting through the website https://arc.cnf.io/sessions/mkky/#!/dashboard that will be opened for input on March 1, 2021.
It is imperative that the meeting be held on this date to
accommodate the scheduling priorities of the key participants.
Patricia Rausch,
Advisory Committee Management Officer, National Aeronautics and Space
Administration.
[FR Doc. 2021-03372 Filed 2-18-21; 8:45 am]
BILLING CODE 7510-13-P